New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?
Journal of Personalized Medicine · 29.07.2024 · 14 (8) · 798
DOI: 10.3390/jpm14080798 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Journal of Personalized Medicine, online erschienen am 29.07.2024. Verfasst von Marzia Tagliaferro und 7 weiteren Autor:innen. Beteiligte Einrichtung: Dipartimento di Patologia Clinica, Ospedale Santa Maria Goretti, A.U.S.L. Latina, 04100 Latina, Italy. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 165 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS.
Abstract (Originalsprache)
Chronic liver diseases (CLD) stem from various causes and lead to a gradual progression that ultimately may result in fibrosis and eventually cirrhosis. This process is typically prolonged and asymptomatic, characterized by the complex interplay among various cell types, signaling pathways, extracellular matrix components, and immune responses. With the prevalence of CLD increasing, diagnoses are often delayed, which leads to poor prognoses and in some cases, the need for liver transplants. Consequently, there is an urgent need for the development of novel, non-invasive methods for the diagnosis and monitoring of CLD. In this context, serum biomarkers—safer, repeatable, and more acceptable alternatives to tissue biopsies—are attracting significant research interest, although their clinical implementation is not yet widespread. This review summarizes the latest advancements in serum biomarkers for detecting hepatic fibrogenesis and advocates for concerted efforts to consolidate current knowledge, thereby providing patients with early, effective, and accessible diagnoses that facilitate personalized therapeutic strategies.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Dipartimento di Patologia Clinica, Ospedale Santa Maria Goretti, A.U.S.L. Latina, 04100 Latina, Italy.
- Dipartimento di Medicina e Chirurgia Traslazionale, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Fondazione Policlinico Universitario "A. Gemelli" IRCCS, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
- Clinical Pathology Unit and Cancer Biobank, Department of Research and Advanced Technologies, I.R.C.C.S. Regina Elena National Cancer Institute, 00144 Rome, Italy.
- Clinical Pathology Unit, San Pietro Fatebenefratelli Hospital, 00189 Rome, Italy.
- Dipartimento di Neuroscienze, Sezione di Fisica, Università Cattolica del Sacro Cuore, 00168 Rome, Italy.
ORCID-Profile: Mariapaola Marino, Valerio Basile, Umberto Basile
Förderung
- Università Cattolica del Sacro Cuore, Fondazione Policlinico Universitario “A. Gemelli” IRCCS
Zitieren
APA
Tagliaferro, M., Marino, M., Basile, V., Pocino, K., Rapaccini, G. L., Ciasca, G., Basile, U., & Carnazzo, V. (2024). New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?. Journal of Personalized Medicine, 14(8), 798. https://doi.org/10.3390/jpm14080798
Vancouver
Tagliaferro M, Marino M, Basile V, Pocino K, Rapaccini GL, Ciasca G, et al. New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?. Journal of Personalized Medicine. 2024;14(8):798. doi:10.3390/jpm14080798
BibTeX
@article{Tagliaferro2024,
author = {Tagliaferro, Marzia and Marino, Mariapaola and Basile, Valerio and Pocino, Krizia and Rapaccini, Gian Ludovico and Ciasca, Gabriele and Basile, Umberto and Carnazzo, Valeria},
title = {New Biomarkers in Liver Fibrosis: A Pass through the Quicksand?},
journal = {Journal of Personalized Medicine},
year = {2024},
volume = {14},
number = {8},
pages = {798},
doi = {10.3390/jpm14080798}
}
EUVIMED